Psychosis
Conditions
Interventions
Group 1: Patients are observed in 6 visits over a period of 2 years. Both self-assessment questionnaires (e.g. attitude to psychiatric medication, patient satisfaction, quality of life, stigma, ...) a
Sponsors
Klinik für Psychiatrie, Psychotherapie und Psychosomatik Vivantes Klinikum Am Urban und Klinikum im Friedrichshain Akademische Lehrkrankenhäuser Charité-Universitätsmedizin Berlin
Eligibility
Sex/Gender
All
Age
18 Years to 40 Years
Inclusion criteria
Inclusion criteria: 1) a diagnosis of a psychotic disorder according to the tenth revision of the International Classification of Mental and Behavioural Disorders (ICD-10;World Health Organization; including diagnoses of substance-induced psychosis F1x.5, schizophrenia-spectrum disorders F2x, mania with psychotic symptoms F30.2, bipolar affective disorder with psychotic symptoms F31.2/F31.5, and severe depression with psychotic symptoms F32.3/F33.3) 2) onset of the first psychotic episode did not exceed five years or presentation to mental health services did not occur more than five years ago 3) willingness to participate in the therapy program at FRITZ 4) sufficient intellectual abilities and proficiency in German to complete study procedures 5) Able to give informed consent.
Exclusion criteria
Exclusion criteria: Patient refuses to participate the Treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improved drug attitude and patient satisfaction six weeks after enrollment in the FRITZ programme compared to pre-treatment as measured with the “Drug Attitude Inventory” (DAI-10, Hogan et al., 1983) and “The Patient Satisfaction Questionnaire Short Form” (PSQ-18, Marshall et al. 1996). | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary Outcomes are: Self-esteem (Rosenberg Self-esteem Scale, RSES, Roth et al., 2008) Selfstigma of Mental Illness Scale (SSMIS, Corrigan et al., 2006) Knowledge About the illness and therapy (COGPIP, Pitschel-Walz et al., 2006) severity of psychotic disorder (Positive and Negative Syndrome Scale, PANNS, Kay et al., 1987, Clinical Global Impression-Schizophrenia Scale, CGI-SCH Scale, Haro et al., 2003) Level of functioning (Global Assessment of Functioning, GAF, Jones et al., 1995) Quality of Life (Q-LES-Q-18 Quality of Life Enjoyment and Satisfaction Questionnaire (Endicott et al 1993) Substance use (Addiction Severity Index, ASI, McLellan et al., 1985) Cognitive measures (Verbaler Lern und Merkfähigkeitstest, VLMT, Helmstädter et al., 2001; Regensburger Wortflüssigkeitstest, RWT, Aschenbrenner et al., 2000; Testbatterie zur Aufmerksamkeitsprüfung, TAP, Zimmermann & Finn, 2007) six weeks, one year and two years after start of the treatment | — |
Countries
Germany
Contacts
Public ContactKarolina Leopold
Klinik für Psychiatrie, Psychotherapie und Psychosomatik Vivantes Klinikum Am Urban und Klinikum im Friedrichshain Akademische Lehrkrankenhäuser Charité-Universitätsmedizin Berlin
Outcome results
None listed